期刊
EYE
卷 27, 期 7, 页码 787-794出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/eye.2013.107
关键词
intravitreal injection; anti-vascular endothelial growth factor; bevacizumab; ranibizumab; aflibercept; safety
资金
- Genentech, Inc.
- Regeneron, Inc.
- Abbott, Inc
Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is increasingly used for the treatment of a wide variety of retinal diseases, including age-related macular degeneration, diabetic retinopathy and retinal vascular occlusions, and retinopathy of prematurity. Despite encouraging results in halting the disease and improving the vision, intravitreal injection of anti-VEGF agents may be associated with systemic adverse events and devastating ocular complications. In this review, we provide an overview of safety data for intravitreal injection of common anti-VEGF agents.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据